Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2263-2270

  Hofner, Thomas ^a   Macher Goeppinger, Stephan ^a   Klein, Corinna ^a   Rigo Watermeier, Teresa ^a   Eisen, Christian ^a   Pahernik, Sascha ^a   Hohenfellner, Markus ^a   Trumpp, Andreas ^a   Sprick, Martin R ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Carcinoma, neuroendocrine; Disease models, animal; HGF protein, human; Proto oncogene proteins c met; Urinary bladder

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CELL SURFACE MARKER; SCATTER FACTOR;

ADULT; AGED; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER MODEL; CELL COUNT; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FLOW CYTOMETRY; HEALTH CARE FACILITY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROENDOCRINE BLADDER CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SPHEROID; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84888643233     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.053     Document Type: Article

References (30)

1. Macedo LT, Ribeiro J, Curigliano G et al: Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. Eur J Surg Oncol 2011;37:558.
2. Ali SZ, Reuter VE and Zakowski MF: Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features. Cancer 1997;79:356.
3. Mukesh M, Cook N, Hollingdale AE et al: Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int 2009;103:747.
4. Quek ML, Nichols PW, Yamzon J et al: Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol 2005;174:93.
5. Lynch SP, Shen Y, Kamat A et al: Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013;64:307.
6. Alijo Serrano F, Sanchez-Mora N, Angel Arranz J et al: Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution. Am J Clin Pathol 2007;128:733.
7. Reya T, Morrison SJ, Clarke MF et al: Stem cells, cancer, and cancer stem cells. Nature 2001;414:105.
8. Ludwig TE, Levenstein ME, Jones JM et al: Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006;24:185.
9. Vermeulen L, Todaro M, De Sousa Mello F et al: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 2008;105:13427.
10. Chan KS, Espinosa I, Chao M et al: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009;106:14016.
11. Turke AB, Zejnullahu K, Wu YL et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77.
12. Kong-Beltran M, Stamos J and Wickramasinghe D: The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004;6:75.
13. Uckun FM, Sather H, Reaman G et al: Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 1995;85:873.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983.
15. Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313.
16. Rosen JM and Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670.
17. Gilbert CA and Ross AH: Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 2009;108:1031.
18. Singh SK, Clarke ID, Hide T et al: Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267.
19. Sidhu SS, Nawroth R, Retz M et al: EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 2010;29:4145.
20. Xue YJ, Lu Q and Sun ZX: CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol 2011;28:1363.
21. Han ZD, He HC, Bi XC et al: Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 2010;160:260.
22. Jaiswal S, Jamieson CH, Pang WW et al: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271.
23. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010;29:2672.
24. Li C, Heidt DG, Dalerba P et al: Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030.
25. Kristiansen G, Sammar M and Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004;35:255.
26. Ariza A, Mate JL, Isamat M et al: Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995;177:363.
27. Blomjous CE, Vos W, De Voogt HJ et al: Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 1989;64:1347.
28. Kanteti R, Nallasura V, Loganathan S et al: PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009;89:301.
29. Song J, Li M, Tretiakova M et al: Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med 2010;134:1702.
30. Agarwal N, Sonpavde G and Sternberg CN: Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol 2012;61:950.